BioTuesdays

Category - Markets

Motus GI Holdings
Markets

AGP cuts PT for Motus GI to $3.75 from $6

Alliance Global Partners lowered its price target for Motus GI Holdings (NASDAQ:MOTS) to $3.75 from $6, reflecting a lower sales multiple and reduced estimates after the company’s third quarter report. The stock closed...

November 15, 2019
Arvinas
Markets

Roth starts Arvinas at buy; PT $35

Roth Capital Partners initiated coverage of Arvinas (NASDAQ:ARVN) with a “buy” rating and $35 price target. The stock closed at $28.38 on Nov. 13. Analyst Zegbeh Jallah writes that Arvinas is one of the leaders in the...

November 14, 2019
GlycoMimetics
Markets

Roth resumes coverage of GlycoMimetics at buy; PT $12

Roth Capital Partners resumed coverage of GlycoMimetics (NASDAQ:GLYC) with a “buy” rating and price target of $12. The stock closed at $6.26 on Nov. 13. Analyst Zegbeh Jallah writes that following an August announcement...

November 14, 2019
Bicycle Therapeutics Logo
Markets

Roth starts Bicycle Therapeutics at buy; PT $17

Roth Capital Partners launched coverage of Bicycle Therapeutics (NASDAQ:BCYC) with a “buy” rating and $17 price target. The stock closed at $8.61 on Nov. 13. Bicycle is developing peptides that may be able to deliver a...

November 14, 2019
Harpoon Therapeutics
Markets

Roth starts Harpoon Therapeutics at buy; PT $25

Roth Capital Partners launched coverage of Harpoon Therapeutics (NASDAQ:HARP) with a “buy” rating and price target of $25. The stock closed at $13.51 on Nov. 13. Analyst Zegbeh Jallah writes that Harpoon has a next...

November 14, 2019
Cerus
Markets

BTIG hikes Cerus to buy with $7 PT

BTIG upgraded Cerus (NASDAQ:CERS) to “buy” from “neutral” with a $7 price target. The stock closed at $4.28 on Nov. 12. Cerus is focused on developing the INTERCEPT blood system to enhance blood safety through reducing...

November 13, 2019
Markets

HCW cuts Sunesis Pharma PT to 50 cents from $1.50

H.C. Wainwright lowered its price target for Sunesis Pharmaceuticals (NASDAQ:SNSS) to 50 cents from $1.50, citing a reduction in the probability of success for the vecabrutinib program to 7% from 8%. The stock closed at...

November 13, 2019
Stoke Therapeutics
Markets

BTIG starts Stoke Therapeutics at buy; PT $46

BTIG launched coverage of Stoke Therapeutics (NASDAQ:STOK) with a “buy” rating and $46 price target. The stock closed at $29.79 on Nov. 11. Stoke is focused on technology developed largely by the academic inventors of...

November 12, 2019
Replimune Group Logo
Markets

Roth ups Replimune PT to $30 from $20

Roth Capital Partners raised its price target for Replimune Group (NASDAQ:REPL) to $30 from $20 after the company over the weekend reported evidence of anti-tumor activity for ongoing and expanded programs in cutaneous...

November 11, 2019